Abiomed (ABMD) Tops Q4 EPS by 7c

April 28, 2022 7:03 AM EDT

Abiomed (NASDAQ: ABMD) reported Q4 EPS of $1.16, $0.07 better than the analyst estimate of $1.09. Revenue for the quarter came in at $270 million versus the consensus estimate of $267.67 million.

GUIDANCE:

Abiomed sees FY2023 revenue of $1.14-1.18 billion, versus the consensus of $1.17 billion.

For earnings history and earnings-related data on Abiomed (ABMD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings